Current treatment of atopic dermatitis in adults;Les traitements actuels de la dermatite atopique chez l'adulte

Annales de Dermatologie et de Venereologie

Volumn 130, Issue 2 II, 2003, Pages 266-274

  Descamps, V ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ASCOMYCIN; AZATHIOPRINE; BASILIXIMAB; BENZODIAZEPINE DERIVATIVE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; DOXEPIN; FLUTICASONE; GAMMA INTERFERON; GAMMA LINOLENIC ACID; HYDROCORTISONE; IMMUNOGLOBULIN; KETOCONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; TACROLIMUS; THYMOPENTIN; THYMOSTIMULIN; VALACICLOVIR;

ACNE; ALLERGY; ALTERNATIVE MEDICINE; ANEMIA; ATOPIC DERMATITIS; ENDOCARDITIS; FEVER; HUMAN; HYPOPIGMENTATION; LEUKOPENIA; MASSAGE; NEPHROTOXICITY; NEUROTOXICITY; PHOTOTHERAPY; PSYCHOTHERAPY; REVIEW; SEPTICEMIA; SKIN ATROPHY; TELANGIECTASIA;

ADULT; DERMATITIS, ATOPIC; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 0037310532     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Tofte SJ, Hanifin JM. Current management and therapy of atopic dermatitis. J Am Acad Dermatol 2001;44:S13-16.
2. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet 1998;351:1715-21.
3. Herd RM, Tidman MJ, Prescott RJ, Hunter JAA. Prevalence of atopic eczema in the community: the Lothian Atopic Dermatitis Study. Br J Dermatol 1996;135:18-19.
4. Katoh N, Hirano S, Suehiro M, Ikenaga K, Yamashita T, Sugawara N, et al. Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26. Clin Exp Immunol 2000;121:187-92.
5. Leung DTM, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001;44:S1-12.
6. Brehler R, Hildebrand A, Luger TA. Recent developments in the treatment of atopic eczema. J Am Acad Dermatol 1997;36:983-94.
7. Graham-Brown RA. Atopic dermatitis: predictions, expectations, and outcomes. J Am Acad Dermatol 2001;45(1 Suppl):S61-3.
8. Coenraads PJ, Span L, Jaspers JP, Fidler V. Intensive patient education and treatment program for young adults with atopic eczema. Hautarzt 2001;52:428-33.
9. Loden M, Andersson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). Br J Dermatol 1999;140:264-7.
10. Niedner R, Schölpf E. Clinical efficacy of topical glucocorticoid preparations and other types of dermatics in inflammatory diseases particularly in atopic dermatitis. Curr Problem Dermatol 1993;21:157-69.
11. Crickx B. Question du mois. Comment prescrivez-vous la quantité de dermocorticoïdes à appliquer? Ann Dermatol Venereol 1999;126:547-52.
12. Long CC, Mills CM, Finlay AY. A practical guide to topical therapy in children. Br J Dermatol 1998;138:293-6.
13. Schlagel CA, Sanborn EC. The weights of topical preparation required for total and partial body inunction. J Invest Dermatol 1964;42:253-6.
14. Dubertret L. Eczéma atopique de l'adulte. pp169-171 Thérapeutique dermatologique. Louis Dubertret, Flammarion Editeur 2000.
15. van der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999;140:1114-21.
16. Williams HC. Do topical steroids reduce relapses in adults with atopic dermatitis? Arch Dermatol 1999;135:1530-1.
17. Ebata T, Izumi H, Aizawa H, Kamide R, Niimura M. Effects of nitrazepam on nocturnal scratching in adults with atopic dermatitis: a double-blind placebo-controlled crossover study. Br J Dermatol 1998;138:631-4.
18. Tzaneva S, Seeber A, Schwaiger M, Honigsmann H, Tanew A. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol 2001;45:503-7.
19. Abeck D, Schmidt T, Fesq H, Strom K, Mempel M, Brockow K, et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol 2000;42:254-7.
20. von Kobyletzki G, Pieck C, Hoffmann K, Freitag M, Altmeyer P. Medium-dose UVA1 cold-light phototherapy in the treatment of severe atopic dermatitis. J Am Acad Dermatol 1999;41:931-7.
21. Grundmann-Kollmann M, Behrens S, Podda M, Peter RU, Kaufmann R, Kerscher M. Phototherapy for atopic eczema with narrow-band UVB. J Am Acad Dermatol 1999;40:995-7.
22. Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomized controlled trial. Lancet 2001;357:2012-6.
23. Prinz B, Michelsen S, Pfeiffer C, Plewig G. Long-term application of extracorporeal photochemotherapy in severe atopic dermatitis. J Am Acad Dermatol 1999;40:577-82.
24. Sowden JM, Berth-Jones J, Ross JS, Motley RJ, Marks R, Finlay AY, et al. Double-blind, controlled, cross-over study of cyclosporin in adults with severe refractory atopic dermatitis Lancet 1991;338:137-40.
25. Berth-Jones J, Graham-Brown RA, Marks R, Camp RD, English JS, Freeman K, et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J 1997;136:76-81.
26. Sepp N, Fritsch PO. Can cyclosporin A induce permanent remission of atopic dermatitis? Br J Dermatol 1993;128:213-6.
27. Granlund H, Erkko P, Reitamo S. Long-term follow-up of eczema patients treated with cyclosporine. Acta Derm Venreol 1998;78:40-3.
28. Pacor ML, Biasi D, Di Lorenzo G, Carletto A, Corrocher R. Recenti Prog Med 2001;92:390-1.
29. Zurbriggen B, Wuthrich B, Cachelin AB, Wili PB, Kagi MK. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study. Dermatology 1999;198:56-60.
30. Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol 1999;40:612-4.
31. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatits. Clin Exp Dermatol 2001;26:369-75.
32. Grundmann-Kollmann M, Korting HC, Behrens S, Leiter U, Krahn G, Kaufmann R, et al. Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol 1999;141:175-6.
33. Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000;143:385-91.
34. Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke WH, Kaufmann R, Zollner TM. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001;137:870-3.
35. Hansen ER, Buus S, Deleuran M, Andersen KE. Treatment of atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2000;143:1324-6.
36. Satchell AC, Barnetson RS. Staphylococcal septicaemia complicating treatment of atopic dermatitis with mycophenolate. Br J Dermatol 2000; 143:202-3.
37. Benez A, Fierlbeck G. Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2001;144:638-9.
38. Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998;134:799-804.
39. Jang IG, Yang JK, Lee HJ, Yi JY, Kim HO, Kim CW, et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon-gamma. J Am Acad Dermatol 2000;42:1033-40.
40. Jolles S, Hughes J, Rustin M. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol 2000;142:551-4.
41. Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998;11:396-8.
42. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000;136:999-1006.
43. Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001;44:S39-46.
44. Drake L, Prendergast M, Maher R, Breneman D, Korman N, Satoi Y, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001;44:S65-72.
45. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109:547-55.
46. Reitamo S, van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002;109:540-46.
47. Luger T, van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:788-94.
48. van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low Systemic Exposure after Repeated Topical Application of Pimecrolimus (Elidel®, SDZ ASM 981) in Patients with Atopic Dermatitis. Dermatology 2002;204:63-8.
49. Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol 2001;11:209-13.
50. Chari S, Clark-Loeser L, Shupack J, Washenik K. A role for leukotriene antagonists in atopic dermatitis? Am J Clin Dermatol 2001;2:1-6
51. Kagi MK, Heyer G. Efficacy of basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in a patient with severe chronic atopic dermatitis. Br J Dermatol 2001;145:350-1.
52. Rappaport MJ, Rappaport V. Eyelid dermatitis to red face syndrome to cure: clinical experience in 100 cases. J Am Acad Dermatol 1999;41:435-42.
53. Sugiura H, Uehara M, Hoshino N, Yamaji A. Long-term efficacy of tacrolimus ointment for recalcitrant facial erythema resistant to topical corticosteroids in adult patients with atopic dermatitis. Arch Dermatol 2000;136:1062-3
54. Kawakami T, Soma Y, Morita E, Koro O, Yamamoto S, Nakamura K, et al. Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation. Dermatology 2001;203:32-7.
55. Friedmann PS, Tan BB. Mite elimination-clinical effect on eczema. Allergy 1998;53:97-100.
56. Gutgesell C, Heise S, Seubert S, Seubert A, Domhof S, Brunner E, et al. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. Br J Dermatol 2001;145:70-4.
57. Holm L, Bengtsson A, van Hage-Hamsten M, Ohman S, Scheynius A. Effectiveness of occlusive bedding in the treatment of atopic dermatitis - a placebo-controlled trial of 12 months' duration. Allergy 2001;56:152-8.
58. Henz BM, Jablonska S, van de Kerkhof PC, Stingl G, Blaszczyk M, Vandervalk, et al. Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema. Br J Dermatol 1999;140:685-8.
59. Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol 1999;104:S114-22.
60. Sheehan MP, Rustin MH, Atherton DJ, Buckley C, Harris DW, Brostoff J, et al. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 1992;340:13-7.
61. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technology Assessment 2000;4:39-107.
62. Broberg A, Faergemann J. Topical antimycotic treatment do atopic dermatitis in the head/neck area. A double-blind randomized study. Acta Dermato Venereol 1995;75:46-9.